Evelo Biosciences Return on Equity

Evelo Biosciences (EVLO) currently reports a ROE of 308.34%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Evelo Biosciences's ROE history and peer comparisons.

Evelo Biosciences's ROE of 308.34% is higher than the Healthcare sector average of 11.15%. That is roughly 2664.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Evelo Biosciences's current 308.34% should be judged against Healthcare norms (sector average: 11.15%) and against EVLO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 308.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Evelo Biosciences, and consider following EVLO for alerts when major investors trade the stock.

Evelo Biosciences is classified in the Healthcare sector. On ROE, it currently shows 308.34% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EVLO with unrelated industries.